Feature: Slick Oil Trading. Forget the Long-Term.

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Slick Oil Trading. Forget the Long-Term. On November 12th, as everyone was calling for an oil rally, we noted that oil was more likely to drop to $56.50 prior to any renewed price rise. A few days later the price dropped a bit past our projected
Feature: Rally Rockin' or Rolling Over? Guilty Market Pleasures.

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Rally Rockin' or Rolling Over? Guilty Market Pleasures. Prior to what has become my annual pilgrimage to Las Vegas--I like to lose early so I can enjoy the rest of the trip--I thought it would be prudent to look at the markets; especially since
Feature: Novelos - FDA Green Lights Phase 3 Cancer Study.

Feb 9, 2021

/

09:41 AM PST

Rating

No ratings

Feature: Novelos - FDA Green Lights Phase 3 Cancer Study. The title of today's release (below) from biotech Novelos Therapeutics (OTCBB: NVLT) speaks volumes: "Novelos Therapeutics Gets Green Light From FDA For Phase 3 Development in Lung Cancer". Obviou
Feature: Biophan - Good for Hearts...Great for Portfolios.

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Biophan - Good For Hearts...Great for Portfolios. The late entrepreneur Victor Kiam came to fame and fortune with the phrase: "I liked the product so much, I bought the company". Mr. Kiam would certainly have approved of next generation medical
Feature: Novelos/FDA Meet Friday. DOW 11,000?

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Novelos/FDA Meet Friday. DOW 11,000? As we mentioned on November 8th, biotech Novelos (OTCBB: NVLT) meets with the FDA on December 2nd to discuss its impressive Phase 1/2 results for its NOV-002 treatment for non-small call lung cancer (NSCLC).
<<283  284  285  286  287  288  289  290  291  292  >>